Year archive

Pluri Inc. — 2024 filings

All 146 regulatory filings released by Pluri Inc. (PLUR) in 2024, sourced directly from the official regulator.

146 Filings

2024 Period

2024 filings (146)

Filing	Released	Lang
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute GraftVersus-Host Disease Regulatory Filings	2024-12-19	English
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute GraftVersus-Host Disease Report Publication Announcement	2024-12-19	English
Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025 Regulatory Filings	2024-12-09	English
Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025 Regulatory Filings	2024-12-09	English
Form 8k-The Company received a letter from Nasdaq Stock Market notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1) Delisting Announcement	2024-11-27	English
Form 8k-The Company received a letter from Nasdaq Stock Market notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1) Regulatory Filings	2024-11-27	English
CURRENT REPORT Delisting Announcement	2024-11-27	English
PLURI Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns Regulatory Filings	2024-11-25	English
PLURI Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns Regulatory Filings	2024-11-25	English
Form 10Q For the quarterly period ended September 30, 2024 Interim / Quarterly Report Q1 2024	2024-11-12	English
Form 10Q For the quarterly period ended September 30, 2024 Report Publication Announcement	2024-11-12	English
QUARTERLY REPORT Interim / Quarterly Report Q1 2025	2024-11-12	English
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority Regulatory Filings	2024-10-28	English
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority Regulatory Filings	2024-10-28	English
Form 8k -notification from NASDAQ on compliance with the equity requirement Regulatory Filings	2024-10-01	English
Form 8k -notification from NASDAQ on compliance with the equity requirement Regulatory Filings	2024-10-01	English
CURRENT REPORT Regulatory Filings	2024-10-01	English
FORM 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Liat Zalts Major Shareholding Notification	2024-09-30	English
FORM 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Liat Zalts Report Publication Announcement	2024-09-30	English
Director's Dealing 2024 Director's Dealing	2024-09-30	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Franco-Yehuda Chen Director's Dealing	2024-09-20	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Franco-Yehuda Chen Director's Dealing	2024-09-20	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Yanay Yaky Director's Dealing	2024-09-20	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Yanay Yaky Director's Dealing	2024-09-20	English
Director's Dealing 2024 Director's Dealing	2024-09-20	English
Director's Dealing 2024 Director's Dealing	2024-09-20	English
FORM 10-K For the fiscal year ended June 30, 2024 Annual Report FY 2024	2024-09-18	English
FORM 10-K For the fiscal year ended June 30, 2024 Report Publication Announcement	2024-09-18	English
ANNUAL REPORT Annual Report FY 2024	2024-09-18	English
Received a deficiency letter, or the Nasdaq Letter notifying that it determined to grant the Company an extension of time to regain compliance with the Stockholders’ Equity Requirement until November Delisting Announcement	2024-07-23	English
Received a deficiency letter, or the Nasdaq Letter notifying that it determined to grant the Company an extension of time to regain compliance with the Stockholders’ Equity Requirement until November Report Publication Announcement	2024-07-23	English
CURRENT REPORT Delisting Announcement	2024-07-23	English
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates Regulatory Filings	2024-07-18	English
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates Regulatory Filings	2024-07-18	English
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply Regulatory Filings	2024-07-08	English
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply Report Publication Announcement	2024-07-08	English
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply Regulatory Filings	2024-07-08	English
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply Regulatory Filings	2024-07-08	English
CURRENT REPORT Regulatory Filings	2024-07-08	English
Form 8k- changes in CFO Position Board/Management Information	2024-07-02	English
Form 8k- changes in CFO Position Report Publication Announcement	2024-07-02	English
CURRENT REPORT Board/Management Information	2024-07-02	English
The results of stockholder voting at the 2024 Annual Meeting AGM Information	2024-06-26	English
The results of stockholder voting at the 2024 Annual Meeting Report Publication Announcement	2024-06-26	English
CURRENT REPORT Declaration of Voting Results & Voting Rights Announcements	2024-06-26	English
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges Regulatory Filings	2024-06-18	English
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges Regulatory Filings	2024-06-18	English
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges M&A Activity	2024-06-18	English
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges Regulatory Filings	2024-06-18	English
CURRENT REPORT Capital/Financing Update	2024-06-18	English
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract Regulatory Filings	2024-06-06	English
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract Regulatory Filings	2024-06-06	English
Received a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Delisting Announcement	2024-05-31	English
Received a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Report Publication Announcement	2024-05-31	English
CURRENT REPORT Delisting Announcement	2024-05-31	English
Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale Regulatory Filings	2024-05-20	English
Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale Regulatory Filings	2024-05-20	English
FORM S-8-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933?? Share Issue/Capital Change	2024-05-09	English
FORM S-8-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933?? Report Publication Announcement	2024-05-09	English
FORM S-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 193 Share Issue/Capital Change	2024-05-09	English
FORM S-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 193 Report Publication Announcement	2024-05-09	English
Form 10Q -For the quarterly period ended March 31, 2024 Interim / Quarterly Report Q1 2024	2024-05-09	English
Form 10Q -For the quarterly period ended March 31, 2024 Report Publication Announcement	2024-05-09	English
REGISTRATION STATEMENT Capital/Financing Update	2024-05-09	English
REGISTRATION STATEMENT Capital/Financing Update	2024-05-09	English
QUARTERLY REPORT Interim / Quarterly Report 9M 2024	2024-05-09	English
Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment Regulatory Filings	2024-05-02	English
Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment Regulatory Filings	2024-05-02	English
2023 Annual Report Annual Report FY 2023	2024-05-01	English
2023 Annual Report Report Publication Announcement	2024-05-01	English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held On June 25, 2024 Proxy Solicitation & Information Statement	2024-05-01	English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held On June 25, 2024 AGM Information	2024-05-01	English
ARS Annual Report	2024-05-01	English
DEFINITIVE PROXY STATEMENT Proxy Solicitation & Information Statement	2024-05-01	English
Received a notification letter from Nasdaq notifying the Company that it had regained compliance with the minimum bid price requirement Regulatory Filings	2024-04-17	English
Received a notification letter from Nasdaq notifying the Company that it had regained compliance with the minimum bid price requirement Report Publication Announcement	2024-04-17	English
CURRENT REPORT Regulatory Filings	2024-04-17	English
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method Regulatory Filings	2024-04-08	English
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method Regulatory Filings	2024-04-08	English
FORM 8-K-Effects of the Reverse Split Capital/Financing Update	2024-04-01	English
FORM 8-K-Effects of the Reverse Split Share Issue/Capital Change	2024-04-01	English
CURRENT REPORT Share Issue/Capital Change	2024-04-01	English
The capital consolidation not yet been completed in DTC, trading in the company's shares on TASE will not resume until the capital consolidation in DTC is completed Capital/Financing Update	2024-04-01	Hebrew (modern)
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences Regulatory Filings	2024-03-28	English
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences Regulatory Filings	2024-03-28	English
There will be no trading on March 31, 2024, due a capital consolidation in the company's shares Share Issue/Capital Change	2024-03-27	Hebrew (modern)
Pluri Inc. Announces 1-for-8 Reverse Share Split Delisting Announcement	2024-03-27	English
Pluri Inc. Announces 1-for-8 Reverse Share Split Regulatory Filings	2024-03-27	English
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report Earnings Release FY 2023	2024-03-21	English
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report Regulatory Filings	2024-03-21	English
Announced its participation in upcoming conferences,details Regulatory Filings	2024-03-19	English
Announced its participation in upcoming conferences,details Regulatory Filings	2024-03-19	English
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturingor Announcement Regulatory Filings	2024-03-14	English
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturingor Announcement Regulatory Filings	2024-03-14	English
Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation Regulatory Filings	2024-03-11	English
Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation Regulatory Filings	2024-03-11	English
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board Board/Management Information	2024-03-06	English
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board Regulatory Filings	2024-03-06	English
CEO Updates on Recent Achievements & 2024 Goals Earnings Release Q1 2024	2024-02-28	English
CEO Updates on Recent Achievements & 2024 Goals Report Publication Announcement	2024-02-28	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-02-14	English
PROSPECTUS SUPPLEMENT-Up to $10,000,000 Common Shares Capital/Financing Update	2024-02-13	English
PROSPECTUS SUPPLEMENT-Up to $10,000,000 Common Shares Report Publication Announcement	2024-02-13	English
Pluri entered into a Sales Agreement with A.G.P. Regulatory Filings	2024-02-13	English
Pluri entered into a Sales Agreement with A.G.P. Report Publication Announcement	2024-02-13	English
AMENDMENT NO. 2 TO SCHEDULE 13G Major Shareholding Notification	2024-02-13	English
PROSPECTUS SUPPLEMENT Capital/Financing Update	2024-02-13	English
CURRENT REPORT Capital/Financing Update	2024-02-13	English
Form 10-Q-report for For the quarterly period ended December 31, 2023 Interim / Quarterly Report Q2 2024	2024-02-12	English
Form 10-Q-report for For the quarterly period ended December 31, 2023 Report Publication Announcement	2024-02-12	English
QUARTERLY REPORT Interim / Quarterly Report Q2 2024	2024-02-12	English
AMENDMENT NO. 2 TO SCHEDULE 13G Major Shareholding Notification	2024-02-01	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-01-26	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Franco-Yehuda Chen Director's Dealing	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Franco-Yehuda Chen Director's Dealing	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Aberman Zami Director's Dealing	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Aberman Zami Regulatory Filings	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Yanay Yaky Director's Dealing	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Yanay Yaky Report Publication Announcement	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Levi Rami Avraham Director's Dealing	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Levi Rami Avraham Report Publication Announcement	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Shemesh-Rasmussen Maital Director's Dealing	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Shemesh-Rasmussen Maital Regulatory Filings	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Abony Lorne Kenneth Director's Dealing	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Abony Lorne Kenneth Director's Dealing	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Birger Pinhas Doron Director's Dealing	2024-01-25	English
FORM 4 -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Birger Pinhas Doron Director's Dealing	2024-01-25	English
Director's Dealing 2024 Director's Dealing	2024-01-25	English
Director's Dealing 2024 Director's Dealing	2024-01-25	English
Director's Dealing 2024 Director's Dealing	2024-01-25	English
Director's Dealing 2024 Director's Dealing	2024-01-25	English
Director's Dealing 2024 Director's Dealing	2024-01-25	English
Director's Dealing 2024 Director's Dealing	2024-01-25	English
Director's Dealing 2024 Director's Dealing	2024-01-25	English
Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis-Form 8k Regulatory Filings	2024-01-24	English
Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis-Form 8k Report Publication Announcement	2024-01-24	English
CURRENT REPORT Regulatory Filings	2024-01-24	English
Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis (DUPLICATE REPORT) Environmental & Social Information	2024-01-23	English
Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis (DUPLICATE REPORT) Regulatory Filings	2024-01-23	English
Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis Regulatory Filings	2024-01-23	English
Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis Regulatory Filings	2024-01-23	English
FORM 8-K-Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization Regulatory Filings	2024-01-08	English
FORM 8-K-Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization Report Publication Announcement	2024-01-08	English
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization Regulatory Filings	2024-01-08	English
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization Regulatory Filings	2024-01-08	English
CURRENT REPORT Regulatory Filings	2024-01-08	English

Filings by year

2026 34 filings
2025 186 filings
2024 146 filings
2023 89 filings
2022 102 filings
2021 106 filings
2020 215 filings
2019 136 filings
2018 128 filings
2017 210 filings
2016 182 filings
2015 184 filings
2014 223 filings
2013 172 filings
2012 144 filings
2011 147 filings
2010 50 filings
2009 57 filings
2008 37 filings
2007 35 filings
2006 32 filings
2005 34 filings
2004 32 filings
2003 38 filings
2002 10 filings
2001 2 filings